Mogharrabi et al. performed a clinical trial involving 70 CAD patients with curcumin and showed that curcumin nanomicelle significantly reduced MMP-2 and MMP-9 activities and gene expression compared to a placebo, suggesting it as a novel treatment in secondary prevention of cardiovascular events [169]. This evidence concerns the gene MMP9 and coronary artery disorder.